Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22274820 | 0.87 | ESR2 (0.51) | ESR2JAK2JAK1NR3C2FAP | |
| SCHEMBL19555643 | 0.85 | ESR2 (0.49) | ESR2JAK2JAK1 | |
| SCHEMBL22568444 | 0.84 | ESR2 (0.50) | ESR2JAK2JAK1CAMKK1CAMKK2 | |
| SCHEMBL22568435 | 0.83 | ESR2 (0.49) | ESR2JAK2JAK1 | |
| SCHEMBL22568428 | 0.82 | ESR2 (0.48) | ESR2JAK2JAK1CAMKK1CAMKK2 | |
| SCHEMBL22568312 | 0.81 | ESR2 (0.47) | ESR2JAK2JAK1KDM4ESMN1; SMN2 | |
| SCHEMBL22568400 | 0.81 | ESR2 (0.47) | ESR2JAK2JAK1KDM4EL3MBTL1 | |
| SCHEMBL22568421 | 0.81 | ESR2 (0.47) | ESR2JAK2JAK1CAMKK1CAMKK2 | |
| SCHEMBL21146292 | 0.79 | NR3C2 (0.46) | NR3C2KDM4EL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL19277384 | 0.79 | NR3C2 (0.46) | NR3C2KDM4EL3MBTL1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111230-B2 | Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-20200331887-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-9643972-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331887-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE | IDO1, IDO2, INMT | ESR2 2748/4885JAK2 922/4885JAK1 952/4885 |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | ESR2 1493/4885JAK2 1134/4885JAK1 1436/4885 |
| US-11111230-B2 | Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine | IDO1, IDO2, INMT | ESR2 2748/4885JAK2 922/4885JAK1 952/4885 |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | ESR2 1493/4885JAK2 1134/4885JAK1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.